• DNDi-20_Logo_No-Tagline_EN_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi-20_Logo_No-Tagline_EN_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Press Releases Translations

En acto público, la Coalición Global contra la enfermedad de Chagas incentiva el aumento del acceso al diagnóstico y tratamiento de pacientes con Chagas

Ciudad de México, México — 12 Aug 2014
Share on twitter
Share on facebook
Share on linkedin
Share on email
Share on print

De los 8 millones de personas infectadas en el mundo, 1 millón 100 mil son mexicanas
Durante las jornadas del Congreso Internacional de Parasitología (ICOPA) 2014, que se desarrolla  en la capital mexicana  hasta el 15 de agosto, la Coalición Global contra la enfermedad de Chagas organiza hoy el evento “Levantemos la voz” con la finalidad de lanzar un alerta: de los 8 millones de  pacientes con la enfermedad de Chagas, 99% no son tratados. La propuesta del encuentro es impulsar una alianza entre gobiernos,  sociedad civil, médicos, investigadores y pacientes para discutir acciones simples que pueden ser implementadas para aumentar el acceso a tratamientos y diagnóstico a los pacientes.
[English] [Português]

Datos más recientes de la Organización Panamericana de la Salud  (OPS) revelan que en México existen 1 millón 100 mil personas infectadas y casi 30 millones en riesgo de contraer la enfermedad.  Cada año se registran unos  7.700, casos  por transmisión vectorial y aproximadamente 1.100 niños nacen  con la enfermedad  en el país.[1]

En el encuentro de esta noche, la Coalición Chagas, junto a investigadores, pacientes, expertos en enfermedades olvidadas, y  representantes gubernamentales, examinarán en conjunto una serie de medidas para que se diagnostique y ofrezca tratamiento a las personas infectadas, garantizando  calidad y disponibilidad.

El acceso a tratamientos no es solo una responsabilidad del Estado, pero también de la sociedad civil. Por ejemplo, los médicos deben identificar a las personas en riesgo y seguir las recomendaciones emitida por la Organización Mundial de la Salud para el tratamiento de los pacientes agudos y crónicos. La sociedad civil tiene la responsabilidad de dar visibilidad al problema, colaborando en la difusión del problema y actuar na busca de una solución, brindando apoyo a los más necesitados. Todos juntos, estrechamente involucrados,  un futuro más saludable y equitativo para las 10 millones de personas que sufren por el Chagas en el mundo puede ser alcanzado.

Durante el evento la artista Shelly Xie tambiém realizará una muestra de sand art, seguido de un video sobre las cifras de la enfermedad y la necesidad de tratarla hoy.

La Coalición Global de la Enfermedad de Chagas fue lanzada en la ciudad de Nueva York en diciembre de 2012. Su objetivo es impulsar el acceso al diagnóstico y tratamiento de pacientes con el mal de Chagas y fomentar los esfuerzos globales para estimular la producción de nuevas herramientas para combatir la enfermedad. Está conformada por organizaciones de la sociedad civil (iniciativa Medicamentos para Enfermedades Olvidadas -DNDi, por sus siglas en inglés-), el Instituto de Salud Global de Barcelona (ISGlobal), Fundación Mundo Sano, CEADES, Sabin Vaccine Institute, Baylor College of Medicine y Texas Children ́s Hospital.

La Coalición Global de la Enfermedad de Chagas invita a todos los que quieran participar a sumar esfuerzos al contribuir, intercambiar y agregar conocimiento. La coalición está abierta para que intervengan los referentes científicos, la industria farmacéutica, pacientes y  todos los miembros  de la comunidad de la que formamos parte, a la que afecta el problema directa o indirectamente.

Conferencistas:

  • Pablo Kuri Morales, Secretaria de la Salud, México;
  • Bernard Pécoul, Executive Director, DNDi;
  • Dra. Tamara Mancero. Organización, Panamericana de la Salud, México (tbc);
  • Igor Almeida, University of Texas;
  • Elvira Idalia Hernandéz Cuevas, AMEPACH

Para más información acerca de las organizaciones de la Coalición Global contra la enfermedad de Chagas:

  • iniciativa Medicamentos para Enfermedades Olvidadas (DNDi) – www.dndial.org
  • Instituto de Salud Global de Barcelona (ISGlobal)- www.isglobal.org
  • Fundación Mundo Sano – www.mundosano.org
  • CEADES – www.ceadesbolivia.org
  • Sabin Vaccine Institute – www.sabin.org
  • Baylor College of Medicine y Texas Children ́s Hospital – www.texaschildrens.org; www.bcm.edu

Contactos para la prensa en México:

Catalina de la Puente – CoordinadoraCoalición Global contra la enfermedad de Chagas – chagas@chagascoalition.org – +54 92214631573

Daniel Salman – analista de comunicación DNDi – dsalman@dndi.org – +55 21 9811 2798

Betina Moura – gerente de comunicación DNDi – bmoura@dndi.org – +55 21 99371 0925



[1] PAHO: Estimación cuantitativa de la enfermedad de Chagas en las Américas/Quantitative estimation of Chagas Disease in the Americas. Organización Panamericana de la Salud. Montevideo, Uruguay, 2006. OPS/HDM/CD/425-06.

Partnership Strengthening Capacities Chagas disease

Read, watch, share

Loading...
Woman standing in front of a house
Press releases
2 Feb 2023

Dutch government renews support to DNDi projects on poverty-related diseases that disproportionately impact women

Statements
1 Feb 2023

DNDi interventions at the 152nd session of the WHO Executive Board

Young man sitting in hospital setting
News
25 Jan 2023

It’s time medical innovation reached the 1.7 billion people affected by neglected tropical diseases: World NTD Day 2023

Film Poster Voices of Leishmaniasis: Shushi from India
Videos
25 Jan 2023

Voices of leishmaniasis: Shishu from India

Child receiving treatment
News
20 Jan 2023

DNDi’s 20th year of bringing the best science for the most neglected

Child affected by dengue and her mother at their home in Bangkok, Thailand.
Stories
16 Dec 2022

2022: Six advances in neglected disease research to remember

Statements
2 Dec 2022

DNDi‘s comments on the conceptual zero draft for the consideration of the Intergovernmental Negotiating Body at INB3

Healthcare workers discussing in hospital setting
Press releases
1 Dec 2022

DNDi partners in a new NIHR-funded Global Health Research Group on HIV-associated Fungal Infections (IMPRINT)

VIEW ALL

Help neglected patients

To date, we have delivered twelve new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
Facebook-f
Twitter
Instagram
Linkedin-in
Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License   
We use cookies to track our audience and improve our content. By clicking 'Accept All', you are agreeing to our use of cookies. Click on 'Customize' to accept only some cookies.
Customize
ACCEPT ALL
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-advertisement1 yearSet by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category .
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
CookieLawInfoConsent1 yearRecords the default button state of the corresponding category & the status of CCPA. It works only in coordination with the primary cookie.
PHPSESSIDsessionThis cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
CookieDurationDescription
elementorneverThis cookie is used by the website's WordPress theme. It allows the website owner to implement or change the website's content in real-time.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
CookieDurationDescription
_ga2 yearsThe _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
_ga_16Q5RH3XRG2 yearsThis cookie is installed by Google Analytics.
_gat_UA-10302561-11 minuteA variation of the _gat cookie set by Google Analytics and Google Tag Manager to allow website owners to track visitor behaviour and measure site performance. The pattern element in the name contains the unique identity number of the account or website it relates to.
_gid1 dayInstalled by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.
_hjAbsoluteSessionInProgress30 minutesHotjar sets this cookie to detect the first pageview session of a user. This is a True/False flag set by the cookie.
_hjFirstSeen30 minutesHotjar sets this cookie to identify a new user’s first session. It stores a true/false value, indicating whether it was the first time Hotjar saw this user.
_hjIncludedInPageviewSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's pageview limit.
_hjIncludedInSessionSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's daily session limit.
_hjSession_112884430 minutesHotjar sets this cookie.
_hjSessionUser_11288441 yearHotjar sets this cookie.
CONSENT2 yearsYouTube sets this cookie via embedded youtube-videos and registers anonymous statistical data.
Targeting
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
SAVE & ACCEPT
Powered by CookieYes Logo